FLIXABI — Total Revenue
Biogen FLIXABI — Total Revenue increased by 6.1% to $10.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.8%, from $13.10M to $10.50M. Over 4 years (FY 2021 to FY 2025), FLIXABI — Total Revenue shows a downward trend with a -14.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market share or successful commercialization of the biosimilar, while a decrease may signal increased competition, pricing pressure, or declining demand for the specific therapy.
Detailed definition
This metric represents the total gross revenue generated from the sale of the biosimilar product Flixabi. It reflects th...
Peer comparison
Comparable to biosimilar or generic product revenue lines at other pharmaceutical companies, where performance is often driven by market penetration and pricing strategies relative to the originator drug.
biib_segment_flixabi_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.30M | $24.60M | $24.00M | $22.50M | $20.50M | $19.00M | $19.30M | $20.40M | $20.10M | $20.20M | $16.70M | $17.80M | $13.10M | $16.20M | $16.10M | $13.10M | $14.30M | $15.30M | $9.90M | $10.50M |
| QoQ Change | — | -2.8% | -2.4% | -6.3% | -8.9% | -7.3% | +1.6% | +5.7% | -1.5% | +0.5% | -17.3% | +6.6% | -26.4% | +23.7% | -0.6% | -18.6% | +9.2% | +7.0% | -35.3% | +6.1% |
| YoY Change | — | — | — | — | -19.0% | -22.8% | -19.6% | -9.3% | -2.0% | +6.3% | -13.5% | -12.7% | -34.8% | -19.8% | -3.6% | -26.4% | +9.2% | -5.6% | -38.5% | -19.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's flixabi — total revenue?
- Biogen (BIIB) reported flixabi — total revenue of $10.50M in Q1 2026.
- How has Biogen's flixabi — total revenue changed year-over-year?
- Biogen's flixabi — total revenue decreased by 19.8% year-over-year, from $13.10M to $10.50M.
- What is the long-term trend for Biogen's flixabi — total revenue?
- Over 4 years (2021 to 2025), Biogen's flixabi — total revenue has grown at a -14.7% compound annual growth rate (CAGR), from $99.40M to $52.60M.
- What does flixabi — total revenue mean?
- The total sales revenue generated by the Flixabi biosimilar product.